Bugworks Research gets $18 Million funding

Bugworks Research, a therapeutics company has said that t has raised $18 million in its Series B1 funding round led by Lightrock India along with other existing investors. After the funding, Tejasvi Ravi, representing LightRock India will join the Board of Directors of the company.

The funding will support the company in its clinical development of BWC0977, a board-spectrum anti-bacterial agent. The company said that it will continue to invest in its proprietary drug discovery platforms. The top antibacterial asset BWC0977 of the company is supported by CARB-X. CRAB-X is a global non-profit partnership dedicated to accelerating antibacterial research.

The CEO of Bugworks Research, Anand Anandkumar has said that the company is excited about its lead clinical asset, which is potentially the first novel truly board-spectrum anti-bacterial drug in nearly five decades. 

The founder and CEO of Global Brain Corporation, Yasuhiko Yurimoto has also said that Bugworks is a unique company within its portfolio, focusing on innovation in biotech and life sciences, which can change the world forever.